AI SummaryThis article discusses the potential of the microbial enzyme iron nitrogenase to use carbon dioxide (CO2) as a substrate, indicating its promise for future biotechnologies. The enzyme’s affinity for CO2 could have implications for sustainable production methods and addressing climate change.The remarkable affinity of the microbial enzyme iron nitrogenase for the greenhouse gas CO2… Continue reading A taste for carbon dioxide
Tag: Biochemical Pharmacology
Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8+ T cells and inhibited tumor growth
AI SummaryThis study focuses on targeting the TNFRSF25 receptor with agonistic antibodies and multimeric TL1A proteins to stimulate CD8+ T cells and inhibit tumor growth. The researchers developed TNFRSF25 agonists and tested their effects on mouse tumor models. They found that the agonists activated CD8+ T cells, induced tumor regression, and promoted long-term antitumor immune… Continue reading Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8+ T cells and inhibited tumor growth
[ASAP] Application of Mechanistic Multiparameter Optimization and Large-Scale In Vitro to In Vivo Pharmacokinetics Correlations to Small-Molecule Therapeutic Projects
AI SummaryThis article discusses the application of mechanistic multiparameter optimization and large-scale in vitro to in vivo pharmacokinetics correlations in small-molecule therapeutic projects. It explores how these approaches can help improve the understanding of drug behavior and effectiveness. The research focus is on optimizing drug development and enhancing pharmacokinetic measurements, which could have significant implications… Continue reading [ASAP] Application of Mechanistic Multiparameter Optimization and Large-Scale In Vitro to In Vivo Pharmacokinetics Correlations to Small-Molecule Therapeutic Projects
[ASAP] In Situ Biofilm Affinity-Based Protein Profiling Identifies the Streptococcal Hydrolase GbpB as the Target of a Carolacton-Inspired Chemical Probe
[ASAP] Actionable Predictions of Human Pharmacokinetics at the Drug Design Stage
AI SummaryThis article discusses the development of a method to predict human pharmacokinetics at the drug design stage. This has significant implications for the pharmaceutical industry as it can aid in the development of more effective and safe drugs. The use of computational models to make actionable predictions in pharmacokinetics can potentially streamline the drug… Continue reading [ASAP] Actionable Predictions of Human Pharmacokinetics at the Drug Design Stage
Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways
AI SummaryThis study investigates a high affinity ACE2 antagonist that limits SARS-CoV-2 replication in both the upper and lower airways. The therapeutic agent, RBD-62, developed through in vitro evolution, effectively suppresses virus replication and prevents severe disease from the Delta variant. Importantly, it does not hinder the development of virus-specific immune responses and does not… Continue reading Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways
Synthetic modification of protein surfaces to mediate induced-proximity pharmacology
You have access to this article Please wait while we load your content… Something went wrong. Try again?
[ASAP] Demystifying Functional Parameters for Irreversible Enzyme Inhibitors
AI SummaryThis article likely discusses the process of demystifying functional parameters for irreversible enzyme inhibitors. It may delve into the key factors and measurements involved in understanding and characterizing irreversible enzyme inhibitors, providing insights that could aid in developing more effective inhibitors for various biological processes. The research could have implications for drug design and… Continue reading [ASAP] Demystifying Functional Parameters for Irreversible Enzyme Inhibitors
Low-affinity LFA1-dependent outside-in signaling mediates avidity modulation via the Rabin8–Rab8 axis
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)
AI SummaryIn Phase I trials, davoceticept (ALPN-202) was tested as a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor in patients with advanced solid tumors. The studies (NEON-1 and NEON-2) evaluated the safety and efficacy of davoceticept monotherapy and in combination with pembrolizumab. Results showed clinical benefits, particularly in renal cell carcinoma patients, but two fatal… Continue reading Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)